MoldCo Review: Service Facts and Evidence Limits

MoldCo is a virtual membership platform that advertises clinician services, optional laboratory products, symptom tracking, messaging, and recurring product shipments. The company frames its model around CIRS and mold-related health concerns. CIRS is contested and is not accepted by mainstream allergy and toxicology bodies. The service description does not validate the clinical framework or its optional tests.

MoldCo publishes an onboarding sequence that includes:

• A company intake questionnaire about symptoms, building history, and medical background.
• A company-described provider review and proposed plan.
• Customer approval before listed products ship or are billed.
• Ongoing messaging, symptom tracking, plan changes, and optional product shipments.

These are company-reported workflow facts. They do not establish that CIRS is a validated diagnosis or that an optional body test supports causation or treatment decisions.

MoldCo describes clinician services and three optional testing categories.

1. Home dust test (HERTSMI-2)

MoldCo lists a HERTSMI-2-style dust product in single-room, three-room, and five-room formats. The score is not a diagnosis, clearance, safe-occupancy, or re-entry determination. EPA says ERMI, the related research index, is not recommended for consumer home testing.

2. Blood panel (company-described markers)

MoldCo describes this as a blood panel with varying marker counts, drawn at Labcorp. Those are company product claims. CLIA laboratory status does not establish that a panel diagnoses mold-related illness, and this review does not endorse CIRS interpretations.

3. Genetic risk test (HLA gene typing)

MoldCo lists an HLA gene test and links it to mold-related reactions. That is the company's framing, not a validated diagnosis, causal finding, or basis for a treatment decision.

The company also lists virtual visits, messaging, symptom tracking, proposed plans, and access to recurring products. Those services do not validate CIRS, establish illness or causation, identify a building source, or replace a qualified building investigation.

MoldCo publishes a membership price and separate charges for visits, tests, and recurring products. These listed figures can change.

MoldCo describes a combined monthly range around 150 to 300 dollars once membership and products are included, states that services are HSA and FSA eligible, and says there is no long-term commitment. It does not advertise standard insurance coverage. Price, payment treatment, and subscription terms do not validate CIRS or any optional test.

Company-reported credentials

MoldCo identifies clinicians and a reference laboratory in its marketing. Credentials and CLIA laboratory operations do not validate CIRS, establish a causal mold-illness diagnosis, or validate the company's optional body tests.

The framework is contested

MoldCo's CIRS framing is contested and is not accepted by mainstream allergy and toxicology bodies. This review does not present it as an established diagnosis, a basis for causal conclusions, or a treatment pathway.

MoldCo cites a company metric that 95 percent of a small tracked group reported fewer symptoms in 30 days. The company disclaimer describes a group of about 61 patients and a self-reported symptom count. That marketing metric is not independent clinical validation and does not establish an objective treatment effect, causation, or safe occupancy.

• MoldCo lists virtual access in most states and shipping for some products.
• The company identifies clinicians and says blood panels are processed through Labcorp.
• MoldCo lists a 79-dollar monthly membership, a first month at no charge, and no long-term commitment.
• The platform description includes intake, visits, messaging, symptom tracking, tests, and recurring products.
• The company lists a HERTSMI-2-style dust product, blood panels, and an HLA test.
• MoldCo states that its services are HSA and FSA eligible.

None of these service facts establishes clinical validity or a reliable building decision.

• CIRS is contested and is not accepted by mainstream allergy and toxicology bodies as an established diagnosis or treatment pathway.
• Optional body tests do not establish illness, exposure source, causation, or treatment need.
• A HERTSMI-2-style dust score does not establish remediation scope, clearance, safe occupancy, or re-entry.
• CLIA laboratory operations and clinician credentials do not establish clinical validity.
• MoldCo does not perform a building investigation or locate a moisture source.
• Membership, visits, tests, and recurring products can create substantial out-of-pocket costs.
• The company does not clearly publish turnaround times for all listed tests.

MoldCo is not a suitable source for an evidence-based diagnosis, causal conclusion, treatment pathway, remediation scope, clearance, or occupancy decision. Its optional body tests cannot establish illness or a building source. Its dust score cannot establish safe occupancy or re-entry. Building questions require a qualified building investigation, and health concerns require evaluation under established medical guidance.

MoldCo vs a standard doctor or allergist

A licensed clinician can evaluate symptoms using established guidance and recognized methods for conditions such as allergy and asthma. MoldCo is a paid membership built around a contested CIRS framework. Neither a clinical visit nor a body test performs a building investigation.

MoldCo vs a home mold test kit

A home mold test kit samples a limited location or material from a building. It does not establish a complete source, health cause, remediation scope, clearance, or safe occupancy. MoldCo's HERTSMI-2-style dust product also has those decision limits. See our guide on how to test for mold.

MoldCo vs specialty lab tests (ERMI and mycotoxin panels)

An ERMI test applies a research index to mold-DNA measurements from dust, while a urine mycotoxin panel reports compounds in urine. EPA does not recommend ERMI for routine consumer use, and CDC states urine mycotoxin tests are not FDA-approved for clinical use. Neither establishes illness, causation, source location, clearance, or safe occupancy.

MoldCo vs professional mold inspection and remediation

A qualified building professional can investigate building history, moisture, accessible materials, and a defined sampling question. MoldCo does not perform that work. Its service and test results do not establish remediation scope or clearance.

Bottom line on comparisons: MoldCo is a paid membership, not a building investigation. Its contested CIRS framing and optional body tests should not be used to establish a diagnosis, source, causation, clearance, or safe occupancy.

MoldCo publishes intake, virtual-visit, plan-approval, billing, messaging, cancellation, and product-shipment terms. Those are service-process facts, not medical guidance. This review does not recommend enrolling or ordering optional tests. MoldCo outputs do not establish diagnosis, causation, treatment need, source, remediation scope, clearance, or safe occupancy.

MoldCo publishes membership, clinician-service, optional-product, payment, and subscription details. Those facts do not validate its CIRS framing or optional tests. CIRS is contested and is not accepted by mainstream allergy and toxicology bodies as an established diagnosis or treatment pathway. Do not use the service, body-test results, or dust scores to establish illness, causation, treatment need, a building source, remediation scope, clearance, safe occupancy, or re-entry.